Needham analyst Bernie McTernan reiterates Uber Technologies (NYSE:UBER) with a Buy and maintains $54 price target.
Medtronic Announced ADAPT Study Results Published in The Lancet Diabetes & Endocrinology Show Improved Glycemic Control and Treatment Satisfaction among Those Using MiniMed 780G System vs Insulin Injections
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced results from the Medtronic ADAPT study were published in The Lancet Diabetes & Endocrinology.